The Data and Safety Monitoring Board approves the usage of medium-dose ProTrans in the ongoing clinical trial.

NextCell Pharma AB ("NextCell") announces that CEO Mathias Svahn will present a status update of the ongoing clinical trials at the Stockholm Corporate Finance Life Science Seminar held at Berns in Stockholm today, March 11. NextCell Pharma is currently running two parallel trials with ProTrans (Protrans-1 Phase I/II and ProTrans-Repeat) for the treatment of patients with type 1-diabetes. Ten out of a total of 15 patients in the phase II part of ProTrans-1 (ProTrans 2) have now left the trial and the last patient's last visit is scheduled for the end of June/July 2020. Thereafter, data will

NextCell Pharma AB ("NextCell") announces today, that it has acted as a reference laboratory to assist National Institute for Biological Standards and Control (NIBSC) in the development of a reference reagent for Mesenchymal Stem The NIBSC is a UK based entity and a global leader when it comes to the characterisation, standardisation and control of biological medicines. As part of their activities the NIBSC has been endorsed by the World Health Organization (WHO) to develop and generate a reference for MSCs. The official name of the study/assignment is: “International Collaborative Study to

NextCell Pharma AB (NextCell) a0nnounces they are, in collaboration with Research Institutes of Sweden (RISE) and Your Special Delivery Service, participating in a CAMP organized project titled: ‘Establishing a non-dry ice dependent logistics strategy for cell therapies. The Centre for Advanced Medical Products (CAMP, an initiative of Vinnova) has decided to proceed on the project titled: ‘Establishing a non-dry ice dependent logistics strategy for cell therapies’. The goal of this project is to evaluate the best logistics strategy for cell-based products. This can be done by evaluating

NextCell Pharma AB ("NextCell") presented, in December 2019, efficacy data of ProTrans stem cells in an interim analysis of the ongoing phase I/II trial, ProTrans-1. Patients receiving medium or high dose of ProTrans showed a statistically significant effect as compared to low dose. The company will present data at Swiss Nordic Bio 2020, on February 6 in Zurich. Swiss Nordic Bio is a partnering and investor conference aimed at connecting healthcare innovations, investors and industry. For NextCell this is an opportunity to inform international investors and potential collaborators about

NextCell Pharma AB today publish the Interim Report 1 for the period September 1 - November 30, 2019. “NextCell”, “NXTCL” or “Company” refer to NextCell Pharma AB with organization number 556965-8361.The amount in brackets refers to the corresponding period in the previous year. Note that the Company’s fiscal year is September 1-August 31.  First quarter (2019-09-01 until 2019-11-30) · Operating income amounted to SEK 1 222 087 (73 745). · Operating result amounted to SEK -3 755 926 (-5 440 809).      · Earnings per share* amounted to SEK -0,20 (-0,38). · Cash and bank

NextCell Pharma AB ("NextCell") announces that they have been granted with an extended wholesale distribution authorization from the Medical Products Agency. In October, the NextCell operation were subject to a regular inspection by the Medical Products Agency which resulted in the wholesale distribution authorization being extended for five years. The wholesale distribution authorization allows NextCell to store and distribute the study drug, ProTrans, for use in the clinical trials. In addition to the Medical Products Agency, the Health and Care Inspectorate (IVO) acts as supervisory

NextCell Pharma AB ("NextCell") announces today that the primary efficacy measures have reached significance in the dose-escalation phase of the company’s clinical trial. After one year follow-up, the six patients treated with high- and medium-dose have retained their insulin production significantly better (P <0.01) as compared to the three patients who received a low-dose of the company's stem cell based drug candidate ProTrans. No serious side effects have been reported. "The results very are promising, even though there are only few patients and this part of the clinical trial was an

NextCell Pharma AB ("NextCell") announces that it is chosen as one of the collaborators in the newly Vinnova funded project Vision-driven Health: Sweden a leader in advanced therapies in 2030. Vinnova is investing in establishing five vision-driven innovation environments to meet important health challenges. These include zero vision for malnutrition in the elderly, elimination of cancer as a cause of death and counteracting antibiotic resistance. NextCell is participating in one of the approved five projects: Sweden a leader in advanced therapies in 2030. This project which is